News

"In the first ever comparative Phase 3 head-to-head study of two proteasome inhibitors in relapsed multiple myeloma, Kyprolis in combination with dexamethasone nearly doubled progression-free survival compared to

The data included in the application support the use of Epclusa (SOF/VEL) in adults with all genotypes (GT1-6) of HCV infection. The CHMP positive opinion was adopted following

The milestone payment was triggered by the initial commercial sale of Darzalex in Europe. Earlier this month, the European Commission granted conditional approval to Darzalex to treat adults

The patient will be treated at University Hospital Germans Trias i Pujol in Badalona, Barcelona, Spain. Abivax will undertake the trial at clinical centers in Spain and Belgium,

Flixabi is now approved to treat rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. Flixabi demonstrated comparable safety and equivalent efficacy to Remicade in

Checkpoint will develop and commercialize these small molecule inhibitors in solid tumors. The BET inhibitor program is the subject of an exclusive, worldwide license agreement pursuant to which

On average 50 percent of Hodgkin lymphoma patients relapse after ASCT and those patients with additional risk factors can be at even higher risk of relapse. ADCETRIS after

This follows Kitov’s announcement in December 2015, that KIT-302’s pivotal Phase III trial successfully met its primary efficacy endpoint. Kitov CEO Isaac Israel said: "We are fortunate to

Teduglutide is an analogue of human glucagon like peptide 2 (GLP-2) that enhances key structural and functional adaptations in the intestinal mucosa. The European Commission (EC) will now